CN112912078B - 用于治疗雌激素受体阳性乳腺癌的组合疗法 - Google Patents

用于治疗雌激素受体阳性乳腺癌的组合疗法 Download PDF

Info

Publication number
CN112912078B
CN112912078B CN201980059916.5A CN201980059916A CN112912078B CN 112912078 B CN112912078 B CN 112912078B CN 201980059916 A CN201980059916 A CN 201980059916A CN 112912078 B CN112912078 B CN 112912078B
Authority
CN
China
Prior art keywords
compound
breast cancer
estrogen receptor
alkyl
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980059916.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112912078A (zh
Inventor
艾立克·坎珀
奥列西娅·卡瑞寇
艾德华·T·H·范德赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyi Biomedicine Shanghai Co ltd
Original Assignee
Hengyi Biomedicine Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyi Biomedicine Shanghai Co ltd filed Critical Hengyi Biomedicine Shanghai Co ltd
Publication of CN112912078A publication Critical patent/CN112912078A/zh
Application granted granted Critical
Publication of CN112912078B publication Critical patent/CN112912078B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980059916.5A 2018-09-13 2019-09-13 用于治疗雌激素受体阳性乳腺癌的组合疗法 Active CN112912078B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730837P 2018-09-13 2018-09-13
US62/730,837 2018-09-13
PCT/IB2019/001035 WO2020053664A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of estrogen-receptor positive breast cancer

Publications (2)

Publication Number Publication Date
CN112912078A CN112912078A (zh) 2021-06-04
CN112912078B true CN112912078B (zh) 2023-04-04

Family

ID=69777646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059916.5A Active CN112912078B (zh) 2018-09-13 2019-09-13 用于治疗雌激素受体阳性乳腺癌的组合疗法

Country Status (8)

Country Link
US (1) US20220047563A1 (https=)
EP (1) EP3849550B1 (https=)
JP (1) JP7441213B2 (https=)
CN (1) CN112912078B (https=)
CA (1) CA3110788A1 (https=)
ES (1) ES2993363T3 (https=)
TW (1) TWI841598B (https=)
WO (1) WO2020053664A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥（上海）股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128655A1 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505562A (ja) * 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
CA2915838C (en) * 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
JP6553632B2 (ja) * 2013-11-18 2019-07-31 フォーマ セラピューティクス，インコーポレイテッド Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
WO2016203335A1 (en) * 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017015027A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
WO2018106433A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent
EP3758753A1 (en) * 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128655A1 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anna Marie Mulligan et al.，.Validation of Intratumoral T-betþLymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer.《Cancer Immunol Res》.2016,第4卷(第1期),第41-48页. *
溴化结构域蛋白抑制剂JQ1对人乳腺癌细胞的作用;师柳等;《武汉大学学报（医学版）》;20150531;第36卷(第3期);第378-381页 *

Also Published As

Publication number Publication date
TW202023552A (zh) 2020-07-01
EP3849550A1 (en) 2021-07-21
EP3849550B1 (en) 2024-08-07
WO2020053664A8 (en) 2020-05-07
JP2022500423A (ja) 2022-01-04
CN112912078A (zh) 2021-06-04
TWI841598B (zh) 2024-05-11
ES2993363T3 (en) 2024-12-27
CA3110788A1 (en) 2020-03-19
WO2020053664A1 (en) 2020-03-19
EP3849550A4 (en) 2022-06-01
US20220047563A1 (en) 2022-02-17
JP7441213B2 (ja) 2024-02-29

Similar Documents

Publication Publication Date Title
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
TWI713952B (zh) 作為溴結構域蛋白質抑制劑的化合物和組合物
TWI471133B (zh) 適合作為ｊａｋ及其它蛋白質激酶抑制劑之氮雜吲哚
JP6599852B2 (ja) ブロモドメイン阻害剤としての新規の置換された二環式化合物
DK2858646T3 (en) DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS AS KINASE INHIBITORS IN TREATMENT OF PROLIFERATIVE DISEASES
KR101824300B1 (ko) Wnt 신호전달 억제제로서 화합물, 조성물, 및 그의 용도
KR20110097906A (ko) Ｈｓｐ90 억제제 및 ｍｔｏｒ 억제제를 포함하는 제약 조합물
WO2001083456A1 (en) Condensed heteroaryl derivatives
CN106892916A (zh) Wnt信号通路的吲唑抑制剂及其治疗应用
WO2006015035A1 (en) Useful compounds for hpv infection
US11858938B2 (en) Imidazo-fused heterocycles and uses thereof
CN103965174B (zh) 含有锌结合基的喹唑啉基egfr酪氨酸激酶抑制剂
CN112912075B (zh) 治疗前列腺癌的组合疗法
CN112912078B (zh) 用于治疗雌激素受体阳性乳腺癌的组合疗法
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
HK40053731A (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
HK40053354A (en) Combination therapy for the treatment of prostate cancer
CN101423513A (zh) 胺基嘧啶衍生物、及其制法和药物组合物与用途
HK40053354B (en) Combination therapy for the treatment of prostate cancer
WO2025119352A1 (zh) 一种并环类mat2a抑制剂、包含其的药物组合物及其应用
WO2025087295A1 (zh) 一种pi3k抑制剂及其制备方法和用途
TWI327146B (en) Pyrimidine derivatives for inhibition of cell proliferation
WO2020147582A1 (zh) 环烷基取代的酰胺类衍生物、其制法与医药上的用途
WO2014154026A1 (zh) PI3K和/或mTOR抑制剂的前药

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053731

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 201203 building 10, No. 860, Xinyang Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Hengyi biomedicine (Shanghai) Co.,Ltd.

Address before: Room 413, building 3, 1690 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: Hengyi biomedical technology (Shanghai) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant